Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)

NCT05848284 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this clinical study is to evaluate the safety and clinical efficacy of the VDyne System in the treatment of symptomatic severe tricuspid regurgitation (TR).

Interventions

  • DEVICE VDyne Transcatheter Tricuspid Valve Replacement System

Study Locations (12)

California

  • Cedars-Sinai Medical Center — Los Angeles
  • Los Robles Hospital and Medical Center — Thousand Oaks

Minnesota

  • Minneapolis Heart Institute Foundation — Minneapolis
  • Mayo Clinic - Rochester — Rochester

New York

  • Columbia University Medical Center/NYPH — New York
  • Montefiore Medical Center — The Bronx

Michigan

  • Henry Ford Hospital — Detriot

Ohio

  • The Christ Hospital — Cincinnati

Oregon

  • Oregon Health and Science Unversity — Portland

South Carolina

  • Medical University of South Carolina — Charleston

Tennessee

  • Ascension St. Thomas — Nashville

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-04-01
Est. Completion 2030-11-30
Phase NA

Sponsor

VDyne

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05848284

The ClinicalTrials.gov registry entry for NCT05848284 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VDyne, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Tricuspid Regurgitation appearing as the primary indexed condition, and to 1 intervention — of which VDyne Transcatheter Tricuspid Valve Replacement System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05848284 reports 12 study locations spanning 9 distinct geographic areas — top geographies include California, Minnesota, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05848284 about?

NCT05848284 is a clinical study titled "Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)". The purpose of this clinical study is to evaluate the safety and clinical efficacy of the VDyne System in the treatment of symptomatic severe tricuspid regurgitation (TR).

What is the current status of trial NCT05848284?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-04-01. Estimated completion is 2030-11-30.

What conditions does trial NCT05848284 study?

This clinical trial studies the following conditions: Tricuspid Regurgitation, Tricuspid Valve Disease, Tricuspid Valvular Disorders. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05848284?

The interventions under investigation include: VDyne Transcatheter Tricuspid Valve Replacement System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05848284?

This trial is sponsored by VDyne, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05848284 being conducted?

This trial has 12 study locations across California, Michigan, Minnesota, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial